Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of Pucotenlimab Injection Combined With Becotatug Vedotin for Injection as Perioperative Therapy in Participants With Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Program Director
- Telefoonnummer: 86-21- 67680899
- E-mail: ra_bj@lepubiopharma.com
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100142
- Nog niet aan het werven
- Peking University Cancer Hospital
-
Contact:
- Bin Zhang
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Nog niet aan het werven
- The First Affiliated Hospital of Fujian Medical University
-
Contact:
- Gongbiao Lin
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Werving
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Contact:
- Jinsong Li
-
Guangzhou, Guangdong, China, 510060
- Nog niet aan het werven
- Sun Yat-sen University Cancer Center
-
Contact:
- Xuekui Liu
-
Shantou, Guangdong, China, 515041
- Nog niet aan het werven
- Cancer Hospital of Shantou University Medical College
-
Contact:
- Hanwei Peng
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Nog niet aan het werven
- Guangxi Medical University Cancer Hospital
-
Contact:
- Duoping Wang
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050011
- Nog niet aan het werven
- The Fourth Hospital of Hebei Medical University
-
Contact:
- Juan Li
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Nog niet aan het werven
- Hubei Cancer Hospital
-
Contact:
- Jian Chen
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Nog niet aan het werven
- Hunan Cancer Hospital
-
Contact:
- Hao Tian
-
Changsha, Hunan, China, 410008
- Nog niet aan het werven
- Xiangya Hospital of Central South University
-
Contact:
- Canhua Jiang
-
-
Liaoning
-
Shenyang, Liaoning, China, 110042
- Nog niet aan het werven
- Liaoning Cancer Hospital & Institute
-
Contact:
- Zhendong Li
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200120
- Nog niet aan het werven
- Shanghai East Hospital
-
Contact:
- Ye Guo
-
Shanghai, Shanghai Municipality, China, 200011
- Nog niet aan het werven
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- Yue He
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Nog niet aan het werven
- Zhejiang Cancer Hospital
-
Contact:
- Chao Chen
-
Ningbo, Zhejiang, China, 315040
- Nog niet aan het werven
- Ningbo Medical Center Lihuili Hospital
-
Contact:
- Zhisen Shen
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Life expectancy ≥ 6 months.
- Subjects with histologically confirmed, resectable Stage III-IVA head and neck squamous cell carcinoma (HNSCC) eligible for curative-intent surgery.
- At least one extracranial measurable lesion per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- No severe cardiac dysfunction.
- Must provide tumor tissue sample not previously subjected to radiotherapy.
- Adequate organ function.
- Subjects of childbearing potential must use effective contraception during the study and for 180 days after the last dose.
Exclusion Criteria:
- Primary tumor originating from nasopharynx, nasal cavity, paranasal sinuses, salivary gland, thyroid/parathyroid gland, skin, or unknown primary site (squamous cell carcinoma).
- Head and neck cancer deemed non-resectable by the investigator.
- Prior treatment with anti-PD-1, anti-PD-L1, MMAE/MMAF-based ADC agents, or other T-cell immune checkpoint inhibitors.
- Prior radiotherapy, systemic anti-tumor therapy, or other investigational therapy for head and neck cancer before study entry.
- Major surgery within 4 weeks before study entry, or not fully recovered from surgical toxicities/complications. Minor procedures (e.g., vascular access placement, percutaneous/endoscopic head/neck biopsy, tracheostomy tube exchange) are allowed.
- Grade ≥2 peripheral neuropathy (CTCAE v5.0).
- Active autoimmune disease requiring systemic treatment within 2 years before first dose.
- Receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 2 weeks before first dose.
- Radiologically detectable central nervous system metastases and/or carcinomatous meningitis.
- Uncontrolled pleural, peritoneal, pelvic effusion, or pericardial effusion.
- Any severe or uncontrolled systemic disease.
- Prior or planned allogeneic tissue/solid organ transplantation.
- Known hypersensitivity to any active ingredient or excipient of the study drugs.
- Evidence of active infection including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- Anti-infective therapy within 2 weeks before randomization.
- Stroke or transient ischemic attack within 6 months before enrollment.
- Uncontrolled or poorly controlled cardiac disease.
- Deep or intraluminal bleeding requiring interventional/surgical hemostasis or blood transfusion within 3 months, or current history of coagulopathy.
- Pulmonary embolism or deep vein thrombosis within 3 months.
- History of or current interstitial lung disease, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, bronchospasm, etc.
- Received live vaccine within 30 days before first study dose.
- History of other primary malignancy.
- Positive serum pregnancy test or breastfeeding female.
- Contraindications to study drugs (pucotenlimab and/or becotatug vedotin) or their excipients; severe hypersensitivity (Grade ≥3) to radiotherapy, cisplatin or its analogues.
- Any condition that the investigator considers unsuitable for participation in the trial.
- Grade ≥2 hearing impairment per CTCAE v6.0.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: locally advanced resectable HNSCC Becotatug Vedotin +Pucotenlimab
|
Administrated intravenously
Administrated intravenously
|
|
Placebo-vergelijker: locally advanced resectable HNSCC Placebo +Pucotenlimab
|
Administrated intravenously
Administrated intravenously
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Major Pathological Response (MPR) Rate
Tijdsspanne: From date of surgery until completion of postoperative pathological assessment, up to 8 weeks
|
From date of surgery until completion of postoperative pathological assessment, up to 8 weeks
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Pathological Complete Response (pCR) Rate
Tijdsspanne: From date of surgery until completion of postoperative pathological assessment, up to 8 weeks
|
From date of surgery until completion of postoperative pathological assessment, up to 8 weeks
|
|
Event-Free Survival (EFS)
Tijdsspanne: From date of randomization until the date of disease progression/recurrence with initiation of new anti-tumor therapy, or death from any cause, whichever came first, assessed up to 24 months
|
From date of randomization until the date of disease progression/recurrence with initiation of new anti-tumor therapy, or death from any cause, whichever came first, assessed up to 24 months
|
|
Overall Survival (OS)
Tijdsspanne: From date of randomization until death from any cause, assessed up to 36 months
|
From date of randomization until death from any cause, assessed up to 36 months
|
|
Preoperative Objective Response Rate (ORR)
Tijdsspanne: preoperative ORR will be assessed up to 12 weeks post-randomization
|
preoperative ORR will be assessed up to 12 weeks post-randomization
|
|
actual surgical resection rate
Tijdsspanne: surgical resection rate will be evaluated perioperatively
|
surgical resection rate will be evaluated perioperatively
|
|
R0 resection rate
Tijdsspanne: R0 resection rate will be confirmed up to 8 weeks postoperatively
|
R0 resection rate will be confirmed up to 8 weeks postoperatively
|
|
lymph node downstaging rate
Tijdsspanne: lymph node downstaging rate will be determined up to 8 weeks postoperatively based on comparison of pre- and post-treatment imaging and pathology
|
lymph node downstaging rate will be determined up to 8 weeks postoperatively based on comparison of pre- and post-treatment imaging and pathology
|
|
Incidence of adverse events (AEs) and laboratory abnormalities assessed by CTCAE v6.0
Tijdsspanne: Within 30 days after last dose (30 days + 7 days window)
|
Within 30 days after last dose (30 days + 7 days window)
|
|
Serum Concentration
Tijdsspanne: From randomization through completion of therapy, up to 30 weeks
|
From randomization through completion of therapy, up to 30 weeks
|
|
Incidence of Anti-Drug Antibodies (ADA)
Tijdsspanne: From randomization through completion of therapy, up to 30 weeks
|
From randomization through completion of therapy, up to 30 weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- HX008/MRG003-C004
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .